jilihot download app

jilihot download app (All times Eastern) Schedule subject to change and/or blackouts Thursday, Dec. 19 COLLEGE BASKETBALL (MEN’S) 5 p.m. ESPNU — Chris Paul HBCU Challenge: Norfolk St. vs. Alabama St., Uncasville, Conn. 7:30 p.m. ESPNU — Chris Paul HBCU Challenge: Delaware St. vs. Grambling St., Uncasville, Conn. COLLEGE FOOTBALL 7 p.m. ESPN2 — The R+L Carriers New Orleans Bowl: Georgia Southern vs. Sam Houston St., New Orleans COLLEGE VOLLEYBALL (WOMEN’S) 6:30 p.m. ESPN — NCAA Tournament: Louisville vs. Pittsburgh, Semifinal, Louisville, Ky. 9 p.m. ESPN — NCAA Tournament: Penn St. vs. Nebraska, Semifinal, Louisville, Ky. GOLF 3:30 a.m. GOLF — DP World Tour: The AfrAsia Bank Mauritius Open, First Round, Mont Choisy Le Golf, Grand-Baie, Mauritius 3:30 a.m. (Friday) GOLF — DP World Tour: The AfrAsia Bank Mauritius Open, Second Round, Mont Choisy Le Golf, Grand-Baie, Mauritius NBA BASKETBALL 7 p.m. TNT — Oklahoma City at Orlando TRUTV — Oklahoma City at Orlando (DataCast) 9:30 p.m. TNT — New York at Minnesota TRUTV — New York at Minnesota (DataCast) NBA G-LEAGUE BASKETBALL Noon ESPNU — Winter Showcase: Greensboro vs. South Bay, Orlando, Fla. 1 p.m. NBATV — Winter Showcase: Stockton vs. Iowa, Orlando, Fla. 2:30 p.m. ESPNU — Winter Showcase: Grand Rapids vs. Oklahoma City, Orlando, Fla. 3:30 p.m. NBATV — Winter Showcase: Raptors 905 vs. Rio Grande Valley, Orlando, Fla. 5 p.m. ESPNEWS — Winter Showcase: Capital City vs. Sioux Falls, Orlando, Fla. 7:30 p.m. ESPNEWS — Winter Showcase: Valley vs. Memphis, Orlando, Fla. NFL FOOTBALL 8:15 p.m. PRIME VIDEO — Denver at L.A. Chargers SOCCER (MEN’S) 3 p.m. CBSSN — UEFA Conference League: HJK Helsinki at Real Betis TENNIS 6 a.m. TENNIS — Next Gen ATP Finals: Round Robin 11 a.m. TENNIS — Next Gen ATP Finals: Round Robin 6 a.m. (Friday) TENNIS — Next Gen ATP Finals: Round Robin The Associated Press created this story using technology provided by Data Skrive TV listings provided by LiveSportsOnTV .

Wild melee after college gameChronic Wounds Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, Mechanism of Action, Route of Administration by DelveInsight | Paracrine, Inc, Oneness Biotech, MediWound, PolarityTE 12-12-2024 08:05 PM CET | Health & Medicine Press release from: DelveInsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Wounds pipeline constitutes 3+ key companies continuously working towards developing 3+ Chronic Wounds treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. "Chronic Wounds Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Wounds Market. Some of the key takeaways from the Chronic Wounds Pipeline Report: https://www.delveinsight.com/sample-request/chronic-wounds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel Chronic Wounds treatment therapies with a considerable amount of success over the years. •Chronic Wounds companies working in the treatment market are Paracrine, Inc, Oneness Biotech, MediWound, PolarityTE, and others, are developing therapies for the Chronic Wounds treatment •Emerging Chronic Wounds therapies in the different phases of clinical trials are- ADRCs, ON101, EscharEx, SkinTE, and others are expected to have a significant impact on the Chronic Wounds market in the coming years. •In March 2024, SOLASCURE revealed the release of its CLEANVLU Phase IIa clinical trial findings in the esteemed International Wound Journal, a prominent publication in the wound care field. SolasCure's debut investigational solution, Aurase Wound Gel, comprises a hydrogel that dispenses tarumase (temporary INN), an engineered enzyme sourced from medical maggots. The gel is designed to facilitate wound healing by promoting debridement and preparing the wound bed for recovery. •In February 2024, Cynata Therapeutics Limited has concluded the preliminary assessment of wound size across the initial 16 participants in its phase 1 clinical study of CYP-006TK for diabetic foot ulcers (DFU), spanning up to the 10-week post-treatment evaluation. •In February 2024, PolarityTE has commenced a multi-center, prospective, randomized controlled trial to assess the effectiveness and safety of SkinTE® in treating Wagner 1 diabetic foot ulcers (DFUs), known as COVER DFUs II. The trial aims to evaluate the closure achieved through vascularized epithelial regeneration with SkinTE® for Wagner grade 1 DFUs. Chronic Wounds Overview Chronic wounds are injuries to the skin that fail to progress through the normal stages of healing within an expected timeframe, typically within three months. These wounds often remain open for an extended period, leading to persistent inflammation and delayed healing. Common types of chronic wounds include pressure ulcers, diabetic foot ulcers, venous ulcers, and arterial ulcers. Get a Free Sample PDF Report to know more about Chronic Wounds Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/chronic-wounds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Emerging Chronic Wounds Drugs Under Different Phases of Clinical Development Include: •ADRCs: Paracrine, Inc •ON101: Oneness Biotech •EscharEx: MediWound •SkinTE: PolarityTE Chronic Wounds Route of Administration Chronic Wounds pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as •Oral •Parenteral •Intravenous •Subcutaneous •Topical Chronic Wounds Molecule Type Chronic Wounds Products have been categorized under various Molecule types, such as •Monoclonal Antibody •Peptides •Polymer •Small molecule •Gene therapy Chronic Wounds Pipeline Therapeutics Assessment •Chronic Wounds Assessment by Product Type •Chronic Wounds By Stage and Product Type •Chronic Wounds Assessment by Route of Administration •Chronic Wounds By Stage and Route of Administration •Chronic Wounds Assessment by Molecule Type •Chronic Wounds by Stage and Molecule Type DelveInsight's Chronic Wounds Report covers around 3+ products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further Chronic Wounds product details are provided in the report. Download the Chronic Wounds pipeline report to learn more about the emerging Chronic Wounds therapies https://www.delveinsight.com/sample-request/chronic-wounds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the Chronic Wounds Therapeutics Market include: Key companies developing therapies for Chronic Wounds are - ConvaTec Inc., Smith & Nephew, 3M, and others. Chronic Wounds Pipeline Analysis: The Chronic Wounds pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Wounds with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Wounds Treatment. •Chronic Wounds key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •Chronic Wounds Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Wounds market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Chronic Wounds drugs and therapies https://www.delveinsight.com/sample-request/chronic-wounds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Chronic Wounds Pipeline Market Drivers •The drivers of the chronic wound care market include factors such as the increasing prevalence of chronic diseases like diabetes, cancer, and autoimmune diseases, the growing elderly population, the rise in sports related injuries, and the need for advanced wound care products and treatments. Chronic Wounds Pipeline Market Barriers •With a limited patient population, pharmaceutical companies face challenges in recouping the substantial expenses incurred during the research, development, and clinical trial phases of new treatments. Scope of Chronic Wounds Pipeline Drug Insight •Coverage: Global •Key Chronic Wounds Companies: Paracrine, Inc, Oneness Biotech, MediWound, PolarityTE, and others •Key Chronic Wounds Therapies: ADRCs, ON101, EscharEx, SkinTE, and others •Chronic Wounds Therapeutic Assessment: Chronic Wounds current marketed and Chronic Wounds emerging therapies •Chronic Wounds Market Dynamics: Chronic Wounds market drivers and Chronic Wounds market barriers Request for Sample PDF Report for Chronic Wounds Pipeline Assessment and clinical trials https://www.delveinsight.com/sample-request/chronic-wounds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. Chronic Wounds Report Introduction 2. Chronic Wounds Executive Summary 3. Chronic Wounds Overview 4. Chronic Wounds- Analytical Perspective In-depth Commercial Assessment 5. Chronic Wounds Pipeline Therapeutics 6. Chronic Wounds Late Stage Products (Phase II/III) 7. Chronic Wounds Mid Stage Products (Phase II) 8. Chronic Wounds Early Stage Products (Phase I) 9. Chronic Wounds Preclinical Stage Products 10. Chronic Wounds Therapeutics Assessment 11. Chronic Wounds Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Chronic Wounds Key Companies 14. Chronic Wounds Key Products 15. Chronic Wounds Unmet Needs 16 . Chronic Wounds Market Drivers and Barriers 17. Chronic Wounds Future Perspectives and Conclusion 18. Chronic Wounds Analyst Views 19. Appendix 20. About DelveInsight Related Reports: Chronic Wounds Market https://www.delveinsight.com/report-store/chronic-wounds-market-report?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Chronic Wounds Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Chronic Wounds Epidemiology https://www.delveinsight.com/report-store/chronic-wounds-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Chronic Wounds Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Latest Reports: •Parp Poly Adp-ribose Polymerase Inhibitor Market: https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight •Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market •Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market •Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market •Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market •Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight •Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.

LKI-ICRC seminar discusses contemporary challenges concerning AI and Autonomous Weapons SystemsWhile You Were Sleeping: 5 stories you might have missed, Dec 1, 2024

I thought it was just a regulation wicket: Starc on KL Rahul dismissal

ATLANTA (AP) — The Atlanta Falcons are back in first place in the NFC South and again in control of their playoff hopes. Rookie quarterback Michael Penix Jr. showed the poise in his first NFL start the Falcons will need to take advantage of their opportunity to end a six-year playoff drought. Powered by a big-play defense that produced two pick-6s, a solid starting debut by Penix and two rushing touchdowns by Bijan Robinson, the Falcons cruised past the hapless New York Giants 34-7 on Sunday. On Sunday night, the Falcons (8-7) received the assist they needed when Tampa Bay lost at Dallas . Because the Falcons swept the Buccaneers, they hold the tiebreaker advantage if they remain tied atop the division. The Falcons have games remaining at Washington on Sunday night and at home against Carolina to close the regular season. If Atlanta wins both games, it would win the division and have a home playoff game. The Falcons are assured of their best record since a 10-6 finish under coach Dan Quinn in 2017, their most recent playoff season. Quinn is in his first season as Washington's coach and has led the Commanders (10-5) to three straight wins, including Sunday's 36-33 victory over Philadelphia. Penix, the No. 8 overall pick in this year's NFL draft, was promoted after coach Raheem Morris benched Kirk Cousins. Penix completed 18 of 27 passes for 202 yards with one interception on a pass that should have been caught by tight end Kyle Pitts. Penix is not a dual-threat quarterback, but he showed the ability to escape pressure in the pocket that Cousins lacks following his 2023 Achilles tendon injury. The left-hander's superior arm strength also was immediately obvious. Robinson's production provided a safety net for the offense which helped make for a smooth transition to Penix. Robinson had scoring runs of 2 and 4 yards. Robinson has rushed for 10 touchdowns this season. He's the first Atlanta player with 10 more more rushing touchdowns since Devonta Freeman during the 2016 Super Bowl season. Robinson ran for 94 yards on 22 carries and had 103 yards from scrimmage. His 11th game this season with at least 100 yards from scrimmage are the most for the Falcons since Warrick Dunn's 11 in 2005. Morris said Robinson deserves to be considered with Philadelphia's Saquon Barkley in discussions regarding the league's top running backs. “Bijan has been outstanding all year in the things that he’s able to do," Morris said. “He’s special. If it wasn’t for this other guy out in Philly, he’d get a lot more recognition across the league. But that guy is having a special year, and Bijan’s not far behind him.” With kicker Younghoe Koo on injured reserve and watching from the sideline, Riley Patterson was wide left on his first field-goal attempt from 43 yards. Patterson rebounded to make attempts from 52 and 37 yards. Jessie Bates III and Matthew Judon each had a pick-6 to highlight a day of big plays for the defense. Arnold Ebiketie had his fifth sack of the season and added a fumble recovery. Kaden Ellis added a strip-sack. He also has five sacks this season, including sacks in four consecutive games. It is the longest streak for Atlanta since Patrick Kerney had sacks in five straight games in 2001. There was some thought that a change at quarterback could be good news for Pitts, who often seemed to be missing in action with Cousins running the offense. After all, a tight end often is a natural target for quick passes from a rookie making his first start. Instead, Pitts had a poor start to the Penix era when he bobbled his first pass from the left-hander, creating an interception by cornerback Cor’Dale Flott. Pitts caught a 7-yard pass on his only other target. For the season, Pitts has 41 catches for 543 yards and three touchdowns. There will be much interest in this week's injury report after WR Drake London (hamstring) was hurt in the second half. Morris provided an optimistic postgame outlook on London. CB Antonio Hamilton (quad) did not return after leaving the game in the first half. 8: Bates has four interceptions and four forced fumbles. His combined eight forced turnovers lead the NFL. The game against Jayden Daniels and the Commanders is a reminder Penix was only the fourth of six quarterbacks selected in the first round of the NFL draft. Daniels, from LSU, was the No. 2 overall pick behind Caleb Williams by Chicago. AP NFL: https://apnews.com/hub/nfl

Panos Panay Hands Out 2024 Kindle Paperwhite From Free Banana StallPresident Bola Tinubu has firmly stated that he is not prepared to reduce the size of his cabinet. He made this clear during his first presidential media chat on Monday, addressing concerns about the cost of governance and calls to shrink his cabinet. Responding to a question about whether he plans to reduce the size of his cabinet to cut governance costs, President Tinubu explained his rationale for assembling a large team, emphasising that it was a strategic decision to ensure optimal performance and delivery of his administration’s goals. “I’m not prepared to bring down the size of my cabinet,” the President said. “I saw the need when I put them together. You don’t give somebody an assignment that they cannot fulfill. No. Nigeria is a large country.” The President reiterated that his focus is on achieving efficiency and effectiveness, which he described as the guiding principles behind the composition of his cabinet. He noted that the structure of his team was carefully designed to address the nation’s complex challenges, adding that the nation’s population plays a role in the cabinet size. “Let’s pay attention to efficiency. Efficiency and effectiveness are the hallmark of the philosophy behind that cabinet. I’m not ready to shrink a little bit of it. I need them,” Tinubu asserted. He added, “If you are to entertain over 200 million, just on entertainment, calculate how many stewards you will require. That’s just for entertainment, not the cleaners.” While acknowledging concerns about governance costs, the President’s response underscores his belief that a well-structured and capable team is crucial for achieving his administration’s objectives. His comments suggest that he intends to prioritise performance and results over downsizing, viewing his current cabinet structure as necessary for the tasks ahead. However, this position is likely to generate debate among Nigerians, especially those advocating for leaner government structures to address economic challenges. Melissa Enoch ‎ Follow us on:

None

(All times Eastern) Schedule subject to change and/or blackouts Thursday, Dec. 19 COLLEGE BASKETBALL (MEN’S) 5 p.m. ESPNU — Chris Paul HBCU Challenge: Norfolk St. vs. Alabama St., Uncasville, Conn. 7:30 p.m. ESPNU — Chris Paul HBCU Challenge: Delaware St. vs. Grambling St., Uncasville, Conn. COLLEGE FOOTBALL 7 p.m. ESPN2 — The R+L Carriers New Orleans Bowl: Georgia Southern vs. Sam Houston St., New Orleans COLLEGE VOLLEYBALL (WOMEN’S) 6:30 p.m. ESPN — NCAA Tournament: Louisville vs. Pittsburgh, Semifinal, Louisville, Ky. 9 p.m. ESPN — NCAA Tournament: Penn St. vs. Nebraska, Semifinal, Louisville, Ky. GOLF 3:30 a.m. GOLF — DP World Tour: The AfrAsia Bank Mauritius Open, First Round, Mont Choisy Le Golf, Grand-Baie, Mauritius 3:30 a.m. (Friday) GOLF — DP World Tour: The AfrAsia Bank Mauritius Open, Second Round, Mont Choisy Le Golf, Grand-Baie, Mauritius NBA BASKETBALL 7 p.m. TNT — Oklahoma City at Orlando TRUTV — Oklahoma City at Orlando (DataCast) 9:30 p.m. TNT — New York at Minnesota TRUTV — New York at Minnesota (DataCast) NBA G-LEAGUE BASKETBALL Noon ESPNU — Winter Showcase: Greensboro vs. South Bay, Orlando, Fla. 1 p.m. NBATV — Winter Showcase: Stockton vs. Iowa, Orlando, Fla. 2:30 p.m. ESPNU — Winter Showcase: Grand Rapids vs. Oklahoma City, Orlando, Fla. 3:30 p.m. NBATV — Winter Showcase: Raptors 905 vs. Rio Grande Valley, Orlando, Fla. 5 p.m. ESPNEWS — Winter Showcase: Capital City vs. Sioux Falls, Orlando, Fla. 7:30 p.m. ESPNEWS — Winter Showcase: Valley vs. Memphis, Orlando, Fla. NFL FOOTBALL 8:15 p.m. PRIME VIDEO — Denver at L.A. Chargers SOCCER (MEN’S) 3 p.m. CBSSN — UEFA Conference League: HJK Helsinki at Real Betis TENNIS 6 a.m. TENNIS — Next Gen ATP Finals: Round Robin 11 a.m. TENNIS — Next Gen ATP Finals: Round Robin 6 a.m. (Friday) TENNIS — Next Gen ATP Finals: Round Robin The Associated Press created this story using technology provided by Data Skrive TV listings provided by LiveSportsOnTV .None

With rookie QB Penix showing poise in starting debut, the Falcons again control their playoff hopes

Billionaire tapped to lead NASA not just about SpaceX during Daytona’s Embry-Riddle grad speech

Samantha Dart, co-head of global commodities research at Goldman, published a note to clients outlining five key questions and answers about the US-EU liquefied natural gas trade. This comes just days after President-elect Donald Trump unless Brussels ramped up purchases of American LNG. For context, last Friday, Trump wrote on Truth Social: Dart told clients that the US is already Europe's largest LNG supplier and a key source of supply growth. She said replacing Russian LNG with US LNG imports could raise shipping costs and European prices to incentivize re-routing cargoes. She said such a shift would have minimal impact on US LNG export revenues, as total export capacity remains fixed, adding exporters with long-term contracts with proposed US LNG projects would benefit. However, Europe's decarbonization strategy may limit the willingness of European companies to make long-term NatGas commitments with US exporters. Dart laid out key questions and answers about the US-EU LNG trade that help clients understand that US LNG Gulf exports can "theoretically" replace Russian NatGas flowing into the EU. US LNG exports averaged 91 mt over the past year (Dec23-Nov24), of which 47 mt or 51% were delivered to Europe. US LNG exports to Europe have grown significantly in levels and as a share of total US LNG exports since the European energy crisis in 2022, peaking in 2023 (Exhibit 1). It appears that Goldman believes Trump's 'America First' policy of replacing Russian LNG to Europe with American LNG is "theoretically" possible. By Zerohedge.com

BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leader in digital care, has announced Chief Financial Officer (CFO) Mark Hirschhorn will take on an expanded role as chief operating officer, effective Jan. 1, 2025. Hirschhorn will now oversee the company's operational and growth strategies, including the clinical, sales and marketing teams, while continuing his responsibilities as CFO. This move reflects Amwell’s commitment to scale its innovative solutions to meet the growing demand for digital healthcare. "Since joining Amwell, Mark has proven himself to be a strong leader, and we’re thrilled to have him step into this expanded role," said Ido Schoenberg, M.D., CEO and chairman of Amwell. "Mark’s operational experience, coupled with his extensive financial acumen, will help us continue to streamline the Amwell portfolio of services and pursue core channels of profitable growth while powering the digital care aspirations of our clients. With these changes, we enable a higher level of focus on our mission of connecting and empowering providers, insurers, and innovators to deliver more accessible, affordable, high-quality care for the benefit of all stakeholders. We also solidify our confidence in our path to cash flow positive in 2026." "I am eager to take on the additional responsibilities as COO," said Hirschhorn. "I look forward to working closely with our talented and streamlined leadership team to sharpen our operational focus on key priorities, drive greater efficiencies, optimize cash flow and deliver profitable growth while pursuing our mission to redefine healthcare delivery through technology-driven solutions." As Amwell continues to streamline processes and drive alignment, two executives will leave the company. Chief Commercial and Growth Officer Kathy Weiler, and Chief Operating Officer Kurt Knight, will depart Amwell at the end of the year. Over her tenure, Weiler has contributed to meaningful cost initiatives while transforming the company’s growth organization. Knight has provided substantial leadership over his 14-year tenure, including key roles in strategy, M&A, the company’s IPO, rapidly scaling operations through the COVID-19 pandemic, and building and managing the company’s affiliated network of providers, Amwell Medical Group ® , a strategic service for payer and provider organizations. “Kathy’s leadership led to the creation of a formally structured and professionalized growth organization, which has had a meaningful and lasting impact on our business. Kurt is a foundational partner in Amwell. He has made an incredible contribution to our company over many years. He played a major role in transforming Amwell into the company it is today, and I am forever grateful. I thank both leaders for their contributions to Amwell,” said Schoenberg. About Amwell Amwell is a leading hybrid care, delivery enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that hybrid care delivery will transform healthcare. We offer a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With nearly two decades of experience, Amwell powers the digital care of more than 50 health plans, which collectively represent more than 100 million covered lives, and many of the nation’s largest health systems. For more information, please visit https://business.amwell.com/ . ©2024 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, Amwell Converge TM , Carepoint TM , Amwell Medical Group®, and the Amwell Logo are registered trademarks or trademarks of American Well Corporation. Notice of Ownership All materials contained herein are the property of American Well Corporation and are copyrighted under United States law and applicable international copyright laws and treaty provisions. The materials contained herein are not work product or "work for hire" on behalf of any third party. The materials contained herein constitute the confidential information of American Well Corporation, except for specific data elements provided by third parties, which are the confidential information of such third parties. The content contained herein results from the application of American Well proprietary processes, analytical frameworks, algorithms, business methods, solution construction aids and templates, all of which are and remain the property of American Well Corporation. Trademark Notice All of the trademarks, service marks and logos displayed on these materials (the "Trademark(s)") are registered and unregistered trademarks of American Well Corporation or third parties who have licensed their Trademarks to American Well Corporation. Except as expressly stated in these terms and conditions, you may not reproduce, display or otherwise use any Trademark without first obtaining American Well Corporation's written permission.Some elite US universities favor wealthy students in admissions decisions, lawsuit allegesI find the possible actions of the Trump Administration and Republican controlled Senate/House to be frightening, but I am aware that there is little I can do to alter those actions. My attention is focused on Arizona State politics. Fortunately this paper provides us with Howard Fischer’s excellent coverage of Arizona state politics. Due to current Legislative Districts' voter registration imbalances, little can be done in the next two Legislative elections to wrest control away from the Republicans. The next Independent Redistricting Commission (IRC) meets in 2031 to establish revised voter balances in the 30 Districts. The districts, as created in 2021, assure Republican control of the Legislature until the 2031 IRC redraw. In 2026, the Governor’s office is up for election. Which Party wins that office will have a major impact on the selection process of the five 2031 IRC members ... most importantly the one independent member. Because of this, if change is to occur, it is imperative that a Democratic governor is elected in 2026. Randy Garmon North side Disclaimer: As submitted to the Arizona Daily Star. Follow these steps to easily submit a letter to the editor or guest opinion to the Arizona Daily Star. Respond: Write a letter to the editor | Write a guest opinion Subscribe to stay connected to Tucson. A subscription helps you access more of the local stories that keep you connected to the community. Catch the latest in Opinion Get opinion pieces, letters and editorials sent directly to your inbox weekly!

Why NVIDIA’s Stock Dip is a Golden Opportunity! Analysts Are All In

Previous: jilihot casino super ace register
Next: jilihot group